All news

Wall Street Zen cuts BlossomHill to sell

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Wall Street Zen downgraded BlossomHill Therapeutics (NASDAQ:BLSM) from "hold" to "sell," diverging from a consensus "Moderate Buy" rating among other analysts, whose average price target is $35. The downgrade follows an EPS miss of $8.75 versus an $0.84 consensus. Shares opened up 5.9% at

Read original source

BLSM company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.